Introduction
Sodium-glucose co-transporter 2 (SGLT2) inhibitors have emerged as a pivotal treatment for type 2 diabetes (T2D), offering cardiovascular benefits and improved glycemic control. This study delves into the real-world efficacy and safety of SGLT2 inhibitors, focusing on a diverse patient population.
Study Design and Participants
Conducted at Chungbuk National University Hospital, the study analyzed 715 T2D patients who added SGLT2 inhibitors to their treatment regimen between 2015 and 2019. After exclusions, 596 patients were included, with a focus on elderly (≥75 years) and adult (<75 years) subgroups.
Effectiveness
Significant reductions in HbA1c levels were observed from the initial visit (8.8 ± 1.3%) to the 6-month follow-up (7.5 ± 1.1%), maintaining lower levels throughout the 36-month period. Fasting plasma glucose (FPG) levels and body weight also showed consistent decreases, highlighting the therapeutic benefits of SGLT2 inhibitors.
Safety and Tolerability
The study reported hypoglycemia as the most common adverse event (AE), followed by genitourinary infections (GUI), polyuria, and gastrointestinal issues. Notably, elderly patients experienced a higher incidence of AEs and discontinuation rates compared to their younger counterparts.
Conclusion
While SGLT2 inhibitors demonstrate significant benefits in T2D management, the study underscores the need for cautious use, especially in elderly patients, due to the increased risk of AEs and discontinuation. Further research is essential to optimize treatment strategies and minimize risks associated with SGLT2 inhibitors.
